|Systematic (IUPAC) name|
|Mol. mass||347.854 g/mol|
Eliprodil (SL-82.0715) is a drug which acts as an NMDA antagonist, binding to the polyamine modulatory site. It has neuroprotective and anticonvulsant effects in animal studies, but does not support self-administration or substitute for phencyclidine, and does not produce sedation or amnesia. It was researched for the treatment of stroke and epilepsy but human trials failed to show clear beneficial effects.
- Dereń-Wesołek, A; Maj, J (1993). "Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex". Polish journal of pharmacology 45 (5–6): 467–80.
- Toulmond, S; Serrano, A; Benavides, J; Scatton, B (1993). "Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window". Brain Research 620 (1): 32–41.
- Balster, RL; Nicholson, KL; Sanger, DJ (1994). "Evaluation of the reinforcing effects of eliprodil in rhesus monkeys and its discriminative stimulus effects in rats". Drug and alcohol dependence 35 (3): 211–6.
- Patat, A; Molinier, P; Hergueta, T; Brohier, S; Zieleniuk, I; Danjou, P; Warot, D; Puech, A (1994). "Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist". International clinical psychopharmacology 9 (3): 155–62.
- Reyes, M; Reyes, A; Opitz, T; Kapin, MA; Stanton, PK (1998). "Eliprodil, a non-competitive, NR2B-selective NMDA antagonist, protects pyramidal neurons in hippocampal slices from hypoxic/ischemic damage". Brain Research 782 (1–2): 212–8.
- Kohl, BK; Dannhardt, G (2001). "The NMDA receptor complex: a promising target for novel antiepileptic strategies". Current medicinal chemistry 8 (11): 1275–89.
- Ikonomidou, C; Turski, L (2002). "Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?". Lancet neurology 1 (6): 383–6.